Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 163 results for fibrosis

  1. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

  2. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  3. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

  4. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  5. Quality standards advisory committee members

    Read biographies of the members of our quality standards advisory committee.

  6. Past appeals and decisions

    Past technology appraisal appeals and decisions

  7. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

  8. Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]

    In development Reference number: GID-TA11819 Expected publication date:  03 September 2026

  9. Mucoactive agents:- What is the most clinically and cost-effective dose of rhDNase (dornase alfa; recombinant human deoxyribonuclease) for people with cystic fibrosis?

    for people with cystic fibrosis? Any explanatory notes(if applicable) Why this is important- People with cystic fibrosis...

  10. Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]

    Discontinued Reference number: GID-TA11041

  11. Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)

    Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.

  12. Monitoring pulmonary disease:- Is lung clearance index a useful and cost-effective tool for the routine assessment and monitoring of changes in pulmonary status in people with cystic fibrosis?

    assessment and monitoring of changes in pulmonary status in people with cystic fibrosis? Any explanatory notes(if applicable) Why this...

  13. Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

    This guidance has been updated and replaced by NICE technology appraisal guidance 504.

  14. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

  15. Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]

    In development Reference number: GID-HST10062 Expected publication date:  17 March 2027